Infla Rx N.V. IFRX
We take great care to ensure that the data presented and summarized in this overview for InflaRx N.V. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IFRX
View all-
Suvretta Capital Management, LLC New York, NY5.73MShares$14.6 Million0.35% of portfolio
-
683 Capital Management, LLC New York, NY2.07MShares$5.26 Million0.29% of portfolio
-
Eversept Partners, LP New York, NY1.62MShares$4.12 Million0.2% of portfolio
-
Ubs Oconnor LLC Chicago, IL798KShares$2.03 Million0.08% of portfolio
-
Ikarian Capital, LLC Dallas, TX705KShares$1.79 Million0.19% of portfolio
-
Morgan Stanley New York, NY668KShares$1.7 Million0.0% of portfolio
-
Raymond James Financial Services Advisors, Inc. St. Petersburg, FL381KShares$968,0270.0% of portfolio
-
Raymond James & Associates St Petersburg, FL267KShares$678,3700.0% of portfolio
-
Boothbay Fund Management, LLC New York, NY158KShares$401,4080.01% of portfolio
-
Commonwealth Equity Services, LLC92.5KShares$234,9500.0% of portfolio
Latest Institutional Activity in IFRX
Top Purchases
Top Sells
About IFRX
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Insider Transactions at IFRX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|